Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Source: Globenewswire
Public Offering Announcement: Processa Pharmaceuticals has priced a public offering of 28 million shares of common stock at $0.25 per share, aiming to raise approximately $7 million for ongoing clinical trials and general corporate purposes.
Company Overview: Processa is focused on developing Next Generation Cancer therapies that modify existing FDA-approved drugs to enhance their efficacy and safety for cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
